Cancer Family
Esophageal Neoplasm
CI-CAN-00000174Explore in graph →
Non-malignant555 active trials6 approved drugs12 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000174Explore in graph →
Clinical trials
2,208 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03556228 | VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma | recruiting | Phase 1 / Phase 2 | 242 | VM Oncology, LLCINDUSTRY | 2 | Dec 11, 2025 | clinicaltrials |
| NCT06943521 | A Study of MT-4561 in Patients With Various Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 27 | Tanabe Pharma America, Inc.INDUSTRY | 2 | Dec 11, 2025 | clinicaltrials |
| NCT07061704 |
| Oncolytic Virus in Esophageal Squamous Cell Carcinoma |
| recruiting |
| Phase 1 / Phase 2 |
| 40 |
| Sichuan UniversityOTHER |
| 1 |
| Dec 8, 2025 |
| clinicaltrials |
| NCT02869217 | Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors | active not recruiting | Phase 1 | 22 | University Health Network, TorontoOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT06753747 | A Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell Carcinoma | recruiting | Phase 1 / Phase 2 | 45 | West China HospitalOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT05307835 | Neoantigen Vaccine in Esophagus Cancer Patients Following Neoadjuvant Therapy and Surgical Resection | active not recruiting | Phase 1 | 27 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT03983954 | Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer. | active not recruiting | Phase 1 | 120 | NeoTX Therapeutics Ltd.INDUSTRY | 2 | Nov 28, 2025 | clinicaltrials |
| NCT07196384 | Optical PD-1 and PD-L1 Imaging in Locally Advanced Esophageal Cancer Using Durvalumab-680LT and Nivolumab-800CW(GLOW) | not yet recruiting | Phase 1 | 15 | University Medical Center GroningenOTHER | 0 | Nov 21, 2025 | clinicaltrials |
| NCT05176002 | Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma. | active not recruiting | Phase 1 / Phase 2 | 25 | Fujian Medical University Union HospitalOTHER | 1 | Nov 19, 2025 | clinicaltrials |
| NCT05565417 | Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas | active not recruiting | Phase 1 / Phase 2 | 67 | Immunitas TherapeuticsINDUSTRY | 1 | Oct 16, 2025 | clinicaltrials |
| NCT07179692 | CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors | recruiting | Phase 1 | 108 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Oct 2, 2025 | clinicaltrials |
| NCT07203898 | A Study of IPM514 in Patients With Esophageal Squamous Cell Carcinoma. | not yet recruiting | Phase 1 | 36 | Beijing Immupeutics Medicine Technology LimitedINDUSTRY | 0 | Oct 2, 2025 | clinicaltrials |
| NCT06500052 | A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors | recruiting | Phase 1 | 20 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 18, 2025 | clinicaltrials |
| NCT07154108 | Endostatin Adenovirus With Checkpoint Inhibitor in Advanced Head and Neck or Esophageal Cancer | not yet recruiting | Phase 1 | 40 | Sichuan UniversityOTHER | 1 | Sep 4, 2025 | clinicaltrials |
| NCT06298916 | 64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer(PHANTOM) | recruiting | Phase 1 / Phase 2 | 26 | Lantheus Medical ImagingINDUSTRY | 1 | Aug 12, 2025 | clinicaltrials |
| NCT07108855 | Detection of Upper Gastrointestinal Tumour Depth and Demarcation Using Systemic Administration of Indocyanine Green During Endoscopic Submucosal Dissection(BRIGHT) | recruiting | Phase 1 / Phase 2 | 10 | University Medical Center GroningenOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT06020885 | Fraction Dose Escalation of Split-course Hypofractionated Concurrent Chemoradiotherapy Following Induction Chemo-immunotherapy in Unresectable Locally Advanced Esophageal Squamous Carcinoma: a Phase I Study. | active not recruiting | Phase 1 | 18 | Sun Yat-sen UniversityOTHER | 1 | Jul 21, 2025 | clinicaltrials |
| NCT05086692 | A Beta-only IL-2 ImmunoTherapY Study(ABILITY-1) | recruiting | Phase 1 / Phase 2 | 115 | Medicenna Therapeutics, Inc.INDUSTRY | 7 | Jul 9, 2025 | clinicaltrials |
| NCT06232083 | A Multi Tumor, Open Phase I Clinical Study on the Progression of First-line Anti-tumor Therapy Using Cardonizumab Combined With Pulsed Low-dose Rate External Irradiation (PLDR) | recruiting | Phase 1 | 20 | Anhui Provincial HospitalOTHER_GOV | 1 | Jul 9, 2025 | clinicaltrials |
| NCT06773507 | Phase I Study of BC008-1A Injection in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 80 | Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 9, 2025 | clinicaltrials |
| NCT07034118 | Definitive Proton Radiotherapy Combined With Chemotherapy and Immunotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase I Clinical Study | not yet recruiting | Phase 1 | 23 | Anhui Provincial HospitalOTHER_GOV | 1 | Jun 24, 2025 | clinicaltrials |
| NCT05944237 | HTL0039732 in Participants With Advanced Solid Tumours | recruiting | Phase 1 / Phase 2 | 150 | Cancer Research UKOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT07001592 | Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors(RIOT3) | recruiting | Phase 1 | 18 | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)OTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT05144698 | RAPA-201 Therapy of Solid Tumors | recruiting | Phase 1 / Phase 2 | 37 | Rapa Therapeutics LLCINDUSTRY | 1 | May 14, 2025 | clinicaltrials |
| NCT04166721 | WaKING: Wnt and checKpoint INhibition in Gastric Cancer | active not recruiting | Phase 1 / Phase 2 | 52 | Royal Marsden NHS Foundation TrustOTHER | 1 | Apr 6, 2025 | clinicaltrials |
| NCT06690216 | Evaluation of [18F]AlF-NOTA-PCP2 PET/CT for PD-L1 Detection in Malignant Tumors(PD-L1-PET) | enrolling by invitation | Phase 1 / Phase 2 | 100 | Man HuOTHER | 1 | Mar 30, 2025 | clinicaltrials |
| NCT05473156 | A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies(APT-CUBE) | recruiting | Phase 1 / Phase 2 | 168 | AP Biosciences Inc.INDUSTRY | 1 | Mar 26, 2025 | clinicaltrials |
| NCT05937438 | Postoperative Radiotherapy Followed by Immunotherapy for Locally Advanced Esophageal Carcinoma | recruiting | Phase 1 / Phase 2 | 70 | Anhui Provincial HospitalOTHER_GOV | 1 | Jan 29, 2025 | clinicaltrials |
| NCT06760676 | A Multiple Tumor Species, Open and Multi-center Clinical Study of Alpaloritovorelli Antibodies (QL-1706) Combined with Pulsed Low Dose Rate External Irradiation (PLDR) for Disease Progression After Previous Anti-tumor Therapy | not yet recruiting | Phase 1 | 90 | Anhui Provincial HospitalOTHER_GOV | 0 | Jan 7, 2025 | clinicaltrials |
| NCT06474468 | A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Esophageal Cancer | recruiting | Phase 1 / Phase 2 | 148 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 3, 2025 | clinicaltrials |
| NCT06746961 | Efficacy and Safety of QL1706 Plus Lenvatinib As 2nd Line Theapy in Patients with Metastatic Esophageal Carcinoma After Disease Progression on ICIs Therapy | not yet recruiting | Phase 1 / Phase 2 | 49 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 0 | Dec 24, 2024 | clinicaltrials |
| NCT04278287 | Chemoradiotherapy in Unresectable Esophageal Cancer | recruiting | Phase 1 / Phase 2 | 105 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Dec 13, 2024 | clinicaltrials |
| NCT06532799 | TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer(BAH250) | recruiting | Phase 1 / Phase 2 | 75 | Essen BiotechOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT05215574 | Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 130 | NGM Biopharmaceuticals, IncINDUSTRY | 1 | Oct 10, 2024 | clinicaltrials |
| NCT06558175 | Reirradiation Dose Escalation in Thoracic Cancers(REPAIR) | not yet recruiting | Phase 1 | 48 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 0 | Aug 16, 2024 | clinicaltrials |
| NCT06491134 | Liposomal Irinotecan With Cisplatin and Concurrent Radiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma | not yet recruiting | Phase 1 | 12 | Hebei Medical University Fourth HospitalOTHER | 0 | Jul 8, 2024 | clinicaltrials |
| NCT05187338 | Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 100 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT06303583 | Neoadjuvant Chemoradiotherapy Followed by Sequential Immunotherapy for Thoracic Esophageal Squamous Cell Carcinoma(CRIS) | enrolling by invitation | Phase 1 / Phase 2 | 30 | Qiu GuoqinOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT02735057 | Chemoradiotherapy in Elderly Patients With Oesophagus Cancer(OSAGE) | recruiting | Phase 1 / Phase 2 | 54 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Jan 18, 2024 | clinicaltrials |
| NCT06173986 | Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer | recruiting | Phase 1 / Phase 2 | 50 | Shanghai Chest HospitalOTHER | 1 | Dec 18, 2023 | clinicaltrials |
| NCT05984342 | Adjuvant Chemotherapy in Combination With Tislelizumab in Lymph Node-Positive Esophageal Squamous Cell Carcinoma | recruiting | Phase 1 | 50 | Affiliated Cancer Hospital of Shantou University Medical CollegeOTHER | 1 | Aug 9, 2023 | clinicaltrials |
| NCT03544736 | Safety and Feasibility of Irradiation and Nivolumab in Esophageal Cancer (INEC) | active not recruiting | Phase 1 / Phase 2 | 30 | Oslo University HospitalOTHER | 1 | Mar 22, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Dec 11, 2025source: clinicaltrials